Mukherjee, ManaliKjarsgaard, MelanieRadford, KatherineHuang, ChynnaLeigh, RichardDorscheid, Delbert RLemiere, CatherineBoulet, Louis-PhilippeWaserman, SusanMartin, JamesNair, Parameswaran2019-04-072019-04-072019-04-03Allergy, Asthma & Clinical Immunology. 2019 Apr 03;15(1):21http://hdl.handle.net/1880/110140https://doi.org/10.11575/PRISM/45510Abstract Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demonstrated in asthmatics with persistent airway eosinophilia in a randomised controlled trial till date. From this double-blind, placebo-controlled, multi-centred, randomized parallel group design, we report that omalizumab is possibly inadequate to control sputum eosinophilia, and therefore may not have a steroid-sparing effect, especially in those maintained on oral corticosteroids daily. This needs to be confirmed or refuted in a larger trial, which may be a challenge with respect to recruitment, since there are currently three additional biologics available to prescribe. Trial registration Clinicaltrials.gov, NCT02049294, Registered 30th January 2014, https://clinicaltrials.gov/ct2/show/NCT02049294unknown2019-04-07enThe Author(s)https://doi.org/10.1186/s13223-019-0337-2